In 1978, Mazia pointed out [1] that a recently evolved model organism, classified as belonging to the phylum Falconium, was beginning to occupy a central position in cell-cycle research. These are animals, he said, "which use [Falcon] plastic dishes as shells and feed on research grants". Although they have cell cycles that conform to the standard G1, S, G2 and M phases, Mazia suspected that established cell lines could not adequately illuminate the underlying causal relationships governing cell-cycle progression. The recent controversies and uncertainties concerning the biological roles of the p 1 6 protein emphasize both the value and limitations of studying the Falconian cell cycle.
Xiong, Zhang and Beach [2] first drew our attention to p16 when they discovered that the cyclin D-Cdk4 protein kinase complex was largely replaced by a p16-Cdk4 complex in transformed cell lines. This was surprising in light of the fact that cyclin D1 -and so, presumably, its association with a cyclin-dependent kinase (Cdk) -had been shown to be essential for cell proliferation [3, 4] . But this was just the first of a series of paradoxical observations concerning p16. Shortly thereafter, the p 16 gene was cloned using a yeast two-hybrid genetic screen designed to identify proteins that could bind to Cdk4 [5] . Using recombinant proteins, it was then demonstrated directly that p16 can compete with the D-type cyclins for binding to Cdk4, and that the p16-Cdk4 complex is inactive as a protein kinase; p16 is therefore described as an inhibitor of Cdk4. It had been observed previously that cyclin D1 is over-expressed in some tumors [6] , and this easily fitted our preconceptions that constitutive activation of certain cell-cycle regulatory proteins might contribute to unconstrained cell proliferation. But how could we explain the fact that p16, an inhibitor of Cdk4, was over-expressed in some transformed cells while cyclin D1, an activator of Cdk4, was over-expressed in others?
This question still can not be answered with certainty, because the biological roles of p16 are not yet fully understood. One possible resolution of the paradox, is the idea that elevated p16 expression in tumor cells results from the inactivation of the retinoblastoma-susceptibility gene product, Rb [6] . It is thought that Rb acts as a switch which either prevents or allows cellular entry into, or exit from, the cell cycle depending upon the phosphorylation state of Rb. Cyclin D-Cdk4 complexes are likely to be the critical Rb kinases [7] , and can therefore reverse the inhibitory effect of Rb on cell cycling. In fact, in cell lines lacking functional Rb protein, neither cyclin D1 nor Cdk4 appears to be necessary for cell proliferation, implying that phosphorylation of Rb may be the only essential function of the cyclin D1-Cdk4 complex [8, 9] . If expression of p16 were dependent upon Rb inactivation, then p16 might be part of an inhibitory feedback loop that turns down Cdk4 activity as Rb is phosphorylated and inactivated (although there is very little direct evidence yet to support this idea). This would allow re-accumulation of unphosphorylated Rb, resetting the stage for the next cell cycle (Fig. 1) . Hence, stable inactivation of Rb -by mutation or as a result of its sequestration by viral oncoproteins -would lead to constitutive but futile p16 over-expression, as was originally observed in transformed cell lines [2] .
As predicted by this model (Fig. 1) , it has been shown that over-expression of p16 prevents proliferation of Rb-positive cells, but does not inhibit proliferation of Rb-negative cells [10] . The implication of these results is that p16 normally guards against untimely inactivation of Rb by Cdk4. Accordingly, loss of p16 could lead to constitutive inactivation of Rb and thereby predispose cells to inappropriate proliferation. It is now essential to determine whether the correlation between p16 expression and Rb activity, which has so far been made only in tumorigenic cell lines, is also observed in primary cells, which have not acquired the uncharacterized genetic changes commonly associated with growth in vitro. Specifically, it will be important to know whether primary cells from Rb-/ -mutant mice have high p16 expression, and whether re-introduction of Rb into such cells specifically reduces p16 expression.
If p16 and Rb are inhibitors of the same growth controlling pathway, then loss ofpl6 might have as significant an impact on tumor progression as does loss of Rb, which was originally identified through its tumor suppressor function. The trail leading to the identification of p16 as a tumor suppressor began with genetic linkage studies on hereditary melanoma [11] , which indicated that segment p21 of chromosome 9 contained a hereditary melanoma susceptibility gene, MLM. In addition, other studies found a high incidence of chromosomal rearrangements and loss of heterozygosity at 9p21 in many types of sporadic tumors (for review see [12] ). The simplest hypothesis to explain these findings is that a single important tumor suppressor gene is located at 9 p21; inherited mutations in this gene cause predisposition to melanoma, Fig. 1 . The p 1 6 protein may be part of a negative feedback loop that regulates Rb activity. Phosphorylation of Rb is thought to reverse its inhibitory effect on cell proliferation. In normal cells, the level of p16 may control the phosphorylation state of Rb by determining the amount of active cyclin D-Cdk4 complex. Thus, loss of p16 could lead to constitutive activation of cyclin D-Cdk4, and thereby to constitutive inactivation of Rb and indefinite cell proliferation.
whereas acquired mutations promote more general oncogenic transformation in a variety of tissues.
Cultured melanoma cell lines were used to map deletions within the 9p21 chromosomal region and to define a locus most likely to correspond to the relevant tumor suppressor gene. The region proved to include the p16 gene [13, 14] . This was a potentially profitable discovery as the gene had been cloned only a few months before on the basis of pl6's ability to bind to the cyclin-dependent kinase, Cdk4. But deletions in tumor lines define a region which is usually quite large and hence can contain more than one gene. Thus, in order to pinpoint the involvement of a particular gene in tumorigenesis, tumors must be found in which the gene in question is inactivated by point mutations rather than large deletions. When Kamb et al. [13] found both small mutations and deletions of pl6, not only in melanomas but in a variety of other tumor cell lines, it looked like the culprit might have been identified.
At this point, p16 displayed many essential characteristics of a tumor suppressor gene. First, an inherited syndrome of tumor susceptibility, in this case, familial melanoma, was identified. Then, cytogenetic studies of tumor and normal cells indicated that deletions in chromosome 9p21 segregated within a melanoma pedigree. Exhaustive mapping identified the p16 gene, located within the chromosomal region delineated by markers linked to melanoma susceptibility, and the p16 protein had a function consistent with its being a tumor suppressor. But a complication soon arose when there appeared to be substantially fewer p16 mutations in primary tumor samples than in cell lines derived from tumors. For example, Cairns et al. [15] examined the frequency of p 1 6 mutations in 75 primary tumors, from tissues including lung, bladder, kidney, head/neck and brain. All the tumors displayed allelic loss on 9p, but only two polymorphisms and two mutations of p16 were identified [15] . The authors suggested that an unidentified gene, not p 16, was the primary target of 9p21 allelic loss in a large number of non-melanoma primary tumors, and that the high incidence of p16 loss in cell lines reflected a secondary event that conferred a growth advantage on cells in culture. Numerous other reports have also appeared that question the generality of p16's involvement in sporadic tumors exhibiting allelic loss at 9p21 [16, 17] . Kamb et al. [13] had been able to pinpoint p16 as a tumor suppressor gene because of their careful work with tumor cell lines, but had their reliance on cell lines misled them about the prevalence of pl6 mutations in tumors?
Despite these early doubts, the case for p16 involvement in both familial and sporadic tumors associated with mutational change at 9p21 has recently received additional support. Allelic deletions of 9p21-22 were found in 85 % of pancreatic adenocarcinomas, and analysis of pl16 in 27 xenografts and 10 cell lines showed homozygous deletions in 41 % and sequence changes, which were likely to be inactivating, in another 38 % [18] . Sequencing ofp 16 from primary tumor DNA confirmed the observed mutations. In other work, p16 was also found to be mutated in 14/27 esophageal cancers, but not in the surrounding normal tissue [19] .
Most recently, p16 has been analyzed in a large series of xenografts derived from brain and colorectal tumors [20] . Homozygous deletions of p16 were found in 68 % (26/38) of glioblastomas, although no point mutations in the p16 coding region were found in the remaining tumors that lacked p 16 deletions. No changes in p16 -either deletions or mutations -were found in other types of brain (0 out of 19) or colorectal (0 out of 25) tumor xenografts. The absence ofp 16 point mutations in glioblastomas might suggest that a gene other than p16 was the true 'target' of the observed deletions. But at least one deletion appeared to be confined to the p16 gene itself, indicating that its loss may be biologically significant. Nevertheless, the low frequency of p16 point mutations is at least curious, and possibly discouraging for supporters of p 16's role as a tumor suppressor. One intriguing possibility arises from the discovery that pl 6 is located adjacent to a closely related gene, p 15S, which also encodes a Cdk4 inhibitor. In all but one glioblastoma, deletion ofp 16 was accompanied by deletion of p 15 [20] . Thus, the apparent lack of pl 16 point mutations in tumors may be explained by the fact that the deletions that are found in tumors would be much more likely to inactivate both p 15 and pl 16 simultaneously.
There is now strong evidence that at least some hereditary melanomas can be explained by mutations in p 16. In 9/15 families with inherited melanoma linked to 9p21, six pl 1 6 mutations were identified that co-segregated with the occurrence of melanoma [21] . Furthermore, 33/36 family members who had melanomas carried a p 1 6 mutation, whereas families in which melanoma is linked to a locus on chromosome lp36 (also implicated in predisposition to melanoma) did not have p 1 6 mutations. In a similar study, however, Kamb et al. [22] found a much lower incidence of pl6 mutations in familial melanoma: p16 was mutated in only 2/11 families with melanoma linked to the 9p21 locus, although, interestingly, two of these mutations (Gly 93--Trp and Val 118-Asp) were also identified in other families [21] . Large germ-line deletions in p 6 were not found.
There are several potential explanations for the apparent lack of pl6 mutations in some familial melanomas and in many tumors containing 9p21 allelic loss. For instance, there may be another tumor suppressor gene at 9p21, such as p15. Or the frequency of pl16 mutation or inactivation may have been underestimated. Current efforts at locating p16 mutations have focused on the coding regions and splice junctions: it is possible that sequences outside the coding area, such as those affecting gene expression, may be mutated. Alternatively, allelic inactivation by mechanisms other than DNA sequence alterations could occur, such as DNA methylation. In addition, the frequency ofp 16 loss may have been underestimated because of difficulties in detecting homozygous pl 16 deletions in primary tumor samples, which are often contaminated with normal tissue. In fact, the high incidence of p 16 mutations in glioblastomas might have been missed if not for the use of xenografts (which are devoid of non-tumor tissue) to aid in detection of homozygous deletions [20] . Resolution of this issue should be aided by examining the expression of pl 6 mRNA and protein in those cases in which coding-sequence mutations can not be found.
In sum, while the accumulating examples of p 1 6 mutations in tumors provide support for the idea that pl6 plays an important role in some tumors, additional biological tests would certainly help to make the case even stronger. The effects of restoring p6 (and/or p15) expression in tumor cell lines are not yet known; nor has the phenotype of a p 16 'knock-out' mutant mouse been described. In addition, as the type of p6 mutations identified in various tumors increases, a systematic assessment of their effects on pl 6 function will become feasible. One new paradox that has emerged from the tumor studies is that p 1 6 and Rb mutations do not predispose to similar types of tumors. Inherited mutations in p 1 6 are associated with familial melanoma, whereas inherited mutations in Rb are associated with retinoblastoma. This is not easy to reconcile with the simple picture of p16 and Rb functioning within one or two steps of each other along the same biochemical pathway. Some salient features of this key regulatory pathway, or perhaps the complete range of p16 functions, may not be easily appreciated or fully manifest in established cell lines. Many of the remaining questions about p16 should be answered as we progress beyond phylum Falconium and begin to focus on the biological functions of p16 in different cell types in vivo.
